Literature DB >> 14660590

Hydrolysis of third-generation cephalosporins by class C beta-lactamases. Structures of a transition state analog of cefotoxamine in wild-type and extended spectrum enzymes.

Michiyoshi Nukaga1, Sanjai Kumar, Kayoko Nukaga, R F Pratt, James R Knox.   

Abstract

Bacterial resistance to the third-generation cephalosporins is an issue of great concern in current antibiotic therapeutics. An important source of this resistance is from production of extended-spectrum (ES) beta-lactamases by bacteria. The Enterobacter cloacae GC1 enzyme is an example of a class C ES beta-lactamase. Unlike wild-type (WT) forms, such as the E. cloacae P99 and Citrobacter freundii enzymes, the ES GC1 beta-lactamase is able to rapidly hydrolyze third-generation cephalosporins such as cefotaxime and ceftazidime. To understand the basis for this ES activity, m-nitrophenyl 2-(2-aminothiazol-4-yl)-2-[(Z)-methoxyimino]acetylaminomethyl phosphonate has been synthesized and characterized. This phosphonate was designed to generate a transition state analog for turnover of cefotaxime. The crystal structures of complexes of the phosphonate with both ES GC1 and WT C. freundii GN346 beta-lactamases have been determined to high resolution (1.4-1.5 Angstroms). The serine-bound analog of the tetrahedral transition state for deacylation exhibits a very different binding geometry in each enzyme. In the WT beta-lactamase the cefotaxime-like side chain is crowded against the Omega loop and must protrude from the binding site with its methyloxime branch exposed. In the ES enzyme, a mutated Omega loop adopts an alternate conformation allowing the side chain to be much more buried. During the binding and turnover of the cefotaxime substrate by this ES enzyme, it is proposed that ligand-protein contacts and intra-ligand contacts are considerably relieved relative to WT, facilitating positioning and activation of the hydrolytic water molecule. The ES beta-lactamase is thus able to efficiently inactivate third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660590     DOI: 10.1074/jbc.M312356200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.

Authors:  Stathis D Kotsakis; Costas C Papagiannitsis; Eva Tzelepi; Leonidas S Tzouvelekis; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

2.  CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.

Authors:  A Zioga; J M Whichard; S D Kotsakis; L S Tzouvelekis; E Tzelepi; V Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

3.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

4.  X-ray crystallographic analysis of the 6-aminohexanoate cyclic dimer hydrolase: catalytic mechanism and evolution of an enzyme responsible for nylon-6 byproduct degradation.

Authors:  Kengo Yasuhira; Naoki Shibata; Go Mongami; Yuki Uedo; Yu Atsumi; Yasuyuki Kawashima; Atsushi Hibino; Yusuke Tanaka; Young-Ho Lee; Dai-ichiro Kato; Masahiro Takeo; Yoshiki Higuchi; Seiji Negoro
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

5.  Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo.

Authors:  Oliv Eidam; Chiara Romagnoli; Guillaume Dalmasso; Sarah Barelier; Emilia Caselli; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

6.  Crystal structure of Mox-1, a unique plasmid-mediated class C β-lactamase with hydrolytic activity towards moxalactam.

Authors:  Takuma Oguri; Takamitsu Furuyama; Takashi Okuno; Yoshikazu Ishii; Kazuhiro Tateda; Robert A Bonomo; Akiko Shimizu-Ibuka
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  Kinetic properties of four plasmid-mediated AmpC beta-lactamases.

Authors:  Cédric Bauvois; Akiko Shimizu Ibuka; Almeida Celso; Jimena Alba; Yoshikazu Ishii; Jean-Marie Frère; Moreno Galleni
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

Review 9.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Structure of AmpC beta-lactamase (AmpCD) from an Escherichia coli clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix.

Authors:  Yoshihiro Yamaguchi; Genta Sato; Yuriko Yamagata; Yohei Doi; Jun-ichi Wachino; Yoshichika Arakawa; Koki Matsuda; Hiromasa Kurosaki
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.